Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 6/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.33 |
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DNM1L | O00429 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11303038 | 0.85 | KDM5C (0.38) | KDM4ELMNAALDH1A1DNM1L | |
| SCHEMBL11303140 | 0.84 | BRD4 (0.41) | LMNA | |
| SCHEMBL862408 | 0.79 | BCHE (0.38) | KDM4EHTR1ABCHEACHELMNA | |
| SCHEMBL841840 | 0.78 | BCHE (0.38) | KDM4EHTR1ABCHEACHELMNA | |
| SCHEMBL11306722 | 0.77 | MGLL (0.35) | KDM4ELMNAALDH1A1 | |
| SCHEMBL13132162 | 0.76 | ALDH1A1 (0.40) | KDM4ELMNADRD3ALDH1A1DRD2 | |
| SCHEMBL13492105 | 0.75 | BRD4 (0.49) | KDM4EALDH1A1 | |
| SCHEMBL862163 | 0.73 | GSK3B (0.35) | KDM4EHTR1ABCHEACHEALDH1A1 | |
| SCHEMBL862382 | 0.72 | KDM4E (0.38) | KDM4EHTR1A | |
| SCHEMBL25483531 | 0.72 | MAPT (0.37) | KDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143057-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2012-03-27 | — | — | US | disclosed |
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2010-02-11 | — | — | US | disclosed |
| US-7625930-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLOC OY (FI) | 2009-12-01 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | CLTA, CLTC, FOLH1 | KDM4E 3409/4885HTR1A 4774/4885MAOB 3982/4885 |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | KDM4E 3409/4885HTR1A 4774/4885MAOB 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.